Either documented serious adverse events in humans, or effectively no retrievable evidence base. Dosing figures circulating for these compounds have no scientific foundation.
NO published human pharmacokinetic data exists. A literature search returns only rodent and rabbit studies, none reporting a human half-life, tmax, or clearance. The widely circulated "33 minutes" figure appears only on vendor marketing pages and unreviewed wiki content with no traceable primary study, and is deliberately not reported here. If you see this compound with a confident half-life in any other source, that source is fabricating it.
No validated or regulator-sanctioned dosing exists, Melanotan II is not approved anywhere and no completed dose-ranging safety trial defines a safe dose. Vendor-quoted doses are not clinically validated and are not reproduced here. For harm context only: a documented poisoning involved a man who injected 6 mg subcutaneously (six times the vendor "recommended" starting dose) and developed rhabdomyolysis and renal dysfunction requiring three days of intensive care. That is a toxicity data point, not a dose.
The human literature on Melanotan II consists almost entirely of case reports of harm. There are no efficacy trials and no safety trials. That asymmetry is itself the finding.
SERIOUS DOCUMENTED HARMS. MELANOMA AND MELANOCYTIC CHANGE: multiple peer-reviewed case reports link Melanotan use to melanoma and pre-malignant change, including biopsy-confirmed cutaneous melanoma in a 20-year-old woman three months after a 3-4 week self-injection course, melanoma in situ, atypical melanocytic naevi, and oral mucosal melanoma after nasal-spray use. Also reported: darkening of existing moles and new mole formation. RHABDOMYOLYSIS: a 39-year-old man who injected 6 mg developed sympathomimetic toxicity with creatine kinase rising from 1,760 to 17,773 IU/L at 12 hours and renal injury, requiring three days in intensive care. PRIAPISM: low-flow priapism requiring cavernosal aspiration, irrigation, and intracavernosal phenylephrine; the patient had not recovered erectile function at four-week follow-up. Also reported: posterior reversible encephalopathy syndrome, renal dysfunction, nausea and vomiting. Additional risk from non-sterile illicit preparation and needle sharing. No completed safety trial exists, so the true incidence of these events is unknown.
- Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (Clin Toxicol, 2012) · pubmed
- Melanoma associated with the use of melanotan-II (Dermatology, 2014) · pubmed
- Melanotan-induced priapism: a hard-earned tan (BMJ Case Rep, 2019) · pubmed
- Melanotan-associated melanoma (Br J Dermatol, 2011) · pubmed
- Melanotan-associated melanoma in situ (Australas J Dermatol, 2012) · pubmed
- Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? (2025) · pubmed